Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

NCT01828086 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque-type Psoriasis

Interventions

BIOLOGICAL: CJM112
BIOLOGICAL: Secukinumab
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals